Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 1
2021 pubmed 6 citations

Francisella FlmX broadly affects lipopolysaccharide modification and virulence.

Chin. Chui-Yoke CY; Zhao. Jinshi J; Llewellyn. Anna C AC; Golovliov. Igor I; Sjöstedt. Anders A; Zhou. Pei P; Weiss. David S DS

Key Findings

  • FlmX is a flippase that coordinates multiple steps of lipopolysaccharide (LPS) modification in Francisella.
  • Deleting flmX makes the bacteria >1,000,000‑fold less virulent and unable to resist LL‑37 and polymyxin.
  • FlmX is conserved in other intracellular pathogens, making it a potential target for new anti‑infective drugs.

Practical Outcomes

  • For biohackers, the study mainly highlights a bacterial weakness rather than a new health protocol. It suggests that drugs blocking FlmX could make infections easier to treat, but it doesn’t provide actionable steps for personal supplementation or performance enhancement.

Summary

Researchers discovered that a bacterial protein called FlmX helps harmful germs change their outer coating and avoid being killed by the natural immune peptide LL‑37 and some antibiotics. When the bacteria lose FlmX, they become far less dangerous and far more vulnerable to these defenses.

Abstract

The outer membrane protects Gram-negative bacteria from the host environment. Lipopolysaccharide (LPS), a major outer membrane constituent, has distinct components (lipid A, core, O-antigen) generated by specialized pathways. In this study, we describe the surprising convergence of these pathways through FlmX, an uncharacterized protein in the intracellular pathogen Francisella. FlmX is in the flippase family, which includes proteins that traffic lipid-linked envelope components across membranes. flmX deficiency causes defects in lipid A modification, core remodeling, and O-antigen addition. We find that an F. tularensis mutant lacking flmX is >1,000,000-fold attenuated. Furthermore, FlmX is required to resist the innate antimicrobial LL-37 and the antibiotic polymyxin. Given FlmX's central role in LPS modification and its conservation in intracellular pathogens Brucella, Coxiella, and Legionella, FlmX may represent a novel drug target whose inhibition could cripple bacterial virulence and sensitize bacteria to innate antimicrobials and antibiotics.

Study Information

Provider

pubmed

Year

2021

Date

2021-06-15T00:00:00.000Z

DOI

10.1016/j.celrep.2021.109247

Citations

6

References

31